On April 12, 2026, Sheikh Khaled bin Mohamed bin Zayed Al Nahyan arrived in Beijing, China, marking a significant moment for the United Arab Emirates (UAE) as it rolls out a new R&D tax credit initiative. This visit comes at a pivotal time when the UAE is transitioning its 3D ultrasound market from a high-end niche to a procedural standard, driven by increasing clinical demand.
The newly established R&D tax credit regime, operationalized under Ministerial Decision No. 24 of 2026, offers a headline rate of 50% on qualifying expenditures. This initiative, part of Cabinet Decision No. 215 of 2025, is designed to bolster innovation within the country, particularly in advanced healthcare technologies.
The credit operates on a tiered structure with three levels: 15% for Tier 1, 35% for Tier 2, and 50% for Tier 3, with qualifying expenditures starting from 1 million AED for Tier 1 and going up to 5 million AED for Tier 3. This structure aims to incentivize companies to invest in research and development, thereby enhancing the UAE’s position as a regional reference and training hub for advanced ultrasound applications.
As the installed base refresh cycle accelerates due to software-driven obsolescence, the implications of this tax credit are profound. It not only encourages technological advancement but also ensures compliance with transfer pricing (TP) regulations, making TP compliance a condition precedent to credit qualification.
Moreover, the dual-threshold design of the credit has direct TP implications, as the headcount requirement cannot be satisfied through intra-group secondments recharged from other tax group members. This aspect emphasizes the importance of local investment and employment in the UAE’s economic landscape.
The UAE’s strategic focus on enhancing its healthcare technology sector through such initiatives is crucial for its long-term economic growth and sustainability. This move is expected to attract international companies looking to leverage the UAE’s favorable tax environment and advanced healthcare infrastructure.
As Sheikh Khaled engages with Chinese leaders, the discussions are likely to revolve around further collaboration in technology and innovation, reinforcing the UAE’s commitment to becoming a global leader in healthcare advancements.
In summary, the convergence of Sheikh Khaled’s visit and the launch of the R&D tax credit signifies a critical step for the UAE in fostering a robust innovation ecosystem. The developments in the ultrasound market and the broader implications for R&D investment underscore the UAE’s strategic vision for the future.
